Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alkermes Plc (NQ: ALKS )

27.04 -0.31 (-1.13%)
Streaming Delayed Price Updated: 3:18 PM EST, Feb 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 324,513
Open 27.33
Bid (Size) 27.03 (4)
Ask (Size) 27.05 (2)
Prev. Close 27.35
Today's Range 27.02 - 27.54
52wk Range 21.75 - 32.79
Shares Outstanding 164,312,356
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Analyst Ratings for Alkermes
 
Via Benzinga
Alkermes's Return On Capital Employed Insights
Benzinga Pro data, Alkermes (NASDAQ:ALKS) reported Q3 sales of $252.36 million. Earnings fell to a loss of $63.97 million, resulting in a 112.28% decrease from last quarter. 
Via Benzinga

Performance

YTD
+4.52%
+4.52%
1 Month
-0.26%
-0.26%
3 Month
+15.95%
+15.95%
6 Month
+5.01%
+5.01%
1 Year
+14.82%
+14.82%

More News

Read More
Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2022
Via Benzinga
Alkermes Plans Separating Its Oncology Unit; Lifts FY22 Earnings Guidance
Via Benzinga
Recap: Alkermes Q3 Earnings
Via Benzinga
Recap: Alkermes Q2 Earnings
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2022
Via Benzinga
Domino's Pizza To Rally 20%? Here Are 5 Other Price Target Changes For Friday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2022
Via Benzinga
Looking Into Alkermes's Return On Capital Employed
Via Benzinga
Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy
Via Benzinga
Earnings Preview: Alkermes
Via Benzinga
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
Via Investor's Business Daily
Sarissa Capital Comments on Alkermes Annual Meeting
From Sarissa Capital Management LP
Via Business Wire
Northrop Grumman Leads 5 Defensive Plays Near Buy Points
Via Investor's Business Daily
Day One Biopharmaceuticals Stock Scores Rising Relative Strength Upgrade
Via Investor's Business Daily
4 Biotech Stocks With Bright Prospects To Buy Amid Recovery
Via Talk Markets
Alkermes Announces 2022 Alkermes Inspiration Grants® Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer
Via 3BL Media
Small-Cap Psychedelic Play Vying for Future Leadership in Addiction Treatment (AXSM, AWKNF, BICX, OPNT, ALKS, PFE, AMPH, OMER)
Via AB Newswire
The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More
Via Benzinga
Best Stocks To Buy Now: June 02, 2022
Via Best Stocks
Topics Artificial Intelligence Cannabis
Exposures Artificial Intelligence Cannabis
Sarissa Condemns Poor Corporate Governance at Alkermes
From Sarissa Capital Management LP
Via Business Wire
New Findings About Life With Bipolar 1 Disorder
Via 3BL Media
Global Central Nervous System Treatment Market Is Expected to Reach $166 Billion In 2028
Via FinancialNewsMedia
Exposures COVID-19
Treating Bipolar 1 Disorder
Via 3BL Media
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.